Arsenic trioxide–induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL

Death Receptors: Signaling and Modulation

1998 • 5,873 citations

The Bcl-2 Protein Family: Arbiters of Cell Survival

1998 • 5,359 citations

Identification and characterization of a new member of the TNF family that induces apoptosis

1995 • 2,890 citations

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 • 2,215 citations

A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA

2013 • 2,176 citations

Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family

1996 • 1,793 citations

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

1997 • 1,694 citations

Regulation of the G2/M transition by p53

2001 • 1,524 citations

An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

1997 • 1,506 citations

Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide

1998 • 1,220 citations

p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53

2000 • 1,155 citations

Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5

2000 • 968 citations

FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2

2000 • 792 citations

Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells

1998 • 671 citations

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

2000 • 526 citations

Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

2000 • 391 citations

Molecular determinants of response to TRAIL in killing of normal and cancer cells.

2000 • 379 citations

Primary dexamethasone treatment of multiple myeloma

1992 • 351 citations

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

1992 • 339 citations

Multiple roles of the tumor suppressor p53

2002 • 335 citations

Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.

2000 • 326 citations

Regulation of p53 Function

2001 • 319 citations

Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.

1999 • 263 citations

Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia

2000 • 258 citations

Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB

1996 • 251 citations

Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL

2000 • 242 citations

Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.

2001 • 195 citations

Retinoic acid (RA) and As ₂ O ₃ treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins

2000 • 193 citations

Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro

1999 • 188 citations

TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

1999 • 158 citations

Intracellular regulation of tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis in human multiple myeloma cells

2002 • 155 citations

The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract

1999 • 151 citations

Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide

1999 • 147 citations

Arsenic trioxide induces apoptosis in human gastric cancer cells through up‐regulation of P53 and activation of caspase‐3

2001 • 133 citations

Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis

2000 • 121 citations

Mutations of the p53 gene in human myeloma cell lines.

1992 • 101 citations

Arsenic Trioxide Induces G2/M Growth Arrest and Apoptosis after Caspase-3 Activation and Bcl-2 Phosphorylation in Promonocytic U937 Cells

2001 • 98 citations

Identification of BAIAP2 (BAI-associated protein 2), a novel human homologue of hamster IRSp53, whose SH3 domain interacts with the cytoplasmic domain of BAI1

1999 • 92 citations

Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.

2000 • 88 citations

The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells.

2000 • 86 citations

Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.

1998 • 81 citations

Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.

1999 • 74 citations

Arsenic Trioxide Inhibits Neuroblastoma Growth in Vivo and Promotes Apoptotic Cell Death in Vitro

2000 • 67 citations

APOPTOSIS-INDUCED BY TRAIL AND TNF-α IN HUMAN MULTIPLE MYELOMA CELLS IS NOT BLOCKED BY BCL-2

1999 • 61 citations

Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice

2000 • 60 citations

Simple Designs and Model-Free Tests for Synergy

1994 • 45 citations

Simple designs and model-free tests for synergy.

1994 • 44 citations

Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells

2001 • 40 citations

Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines

2001 • 33 citations

Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3

2001 • 21 citations

Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines

2001 • 21 citations

Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34+ hematopoietic progenitor cells and normal lymphocytes

2000 • 18 citations

Arsenicals and inhibitors of histone deacetylase as anticancer therapy.

1999 • 17 citations

The role of p53, bcl-2 and bax network in dexamethasone induced apoptosis in multiple myeloma cell lines

1996 • 15 citations

bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines

1996 • 11 citations